The Board of Starpharma announced the appointment of Dr. Jeff Davies as an independent non-executive director, effective 1 April 2022. Dr. Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1 AUD | 0.00% | -16.67% | -41.18% |
08/04 | Starpharma, Medicxi Co-Found Petalion Therapeutics; Shares Surge 16% | MT |
18/03 | Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX Emerging Companies Index | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-41.18% | 27.39M | |
+42.54% | 750B | |
+34.11% | 606B | |
-6.43% | 356B | |
+18.52% | 326B | |
+6.20% | 286B | |
+18.08% | 246B | |
-3.44% | 213B | |
+11.35% | 213B | |
+2.07% | 167B |
- Stock Market
- Equities
- SPL Stock
- News Starpharma Holdings Limited
- Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022